It is currently incompletely understood whether inflammation and neurodegeneration are causally related in multiple sclerosis (MS). The sequence of a potential causal relationship is also unknown. Inflammation is present in rather all clinical stages of MS. Its role in the pathogenesis of MS is supported by histopathological analyses, genetic data, and numerous animal models of MS. All approved disease-modifying therapies that reduce clinical relapses and diminish the accumulation of lesions on neuroimaging are anti-inflammatory. Axonal loss and accelerated brain volume loss can also be detected from clinical disease onset throughout all stages. The expression of neurofilament light chain in cerebrospinal fluid and serum, a scaffolding protein in axons and dendrites, is a biomarker of neuronal injury associated with clinical relapses and reflects neuronal loss during episodes of acute inflammation. The recent association of human endogenous retrovirus (HERV) and its envelope proteins with MS illustrates a pathogenic pathway that causally links central nervous system (CNS)–intrinsic proinflammatory effects and inhibition of myelin repair and neuroregeneration. A review of current data on the causal relationship between inflammation and neurodegeneration in MS identified numerous plausible pathomechanisms that link the two events. Observations from most experimental models appear to favor a pathogenesis in which inflammation precedes neurodegeneration.
MartinRMcFarlandHFMcFarlinDE. Immunological aspects of demyelinating diseases. Annu Rev Immunol1992; 10: 153–187.
2.
KorczynAD. Editorial comments: Is multiple sclerosis a neurodegenerative or inflammatory disease?J Neural Transm2013; 120(10): 1457.
3.
LublinFDReingoldSCCohenJA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83(3): 278–286.
4.
AzevedoCJOvertonEKhadkaS, et al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm2015; 2(3): e102.
5.
CharcotJM. Histologie de la sclerose on plaque. Gaz Hop1868; 141: 554–558.
6.
CompstonAMcDonaldINoseworthyJ, et al. McAlpine’s multiple sclerosis. 4th ed.2005, pp. 3–68. Elsevier.
7.
TrappBDPetersonJRansohoffRM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338(5): 278–285.
8.
KornekBStorchMKWeissertR, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol2000; 157(1): 267–276.
9.
BitschASchuchardtJBunkowskiS, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain2000; 123: 1174–1183.
10.
van WalderveenMAKamphorstWScheltensP, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology1998; 50(5): 1282–1288.
11.
van WaesbergheJHKamphorstWDe GrootCJ, et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol1999; 46(5): 747–754.
12.
MillerDHBarkhofFFrankJA, et al. Measurement of atrophy in multiple sclerosis: Pathological basis, methodological aspects and clinical relevance. Brain2002; 125(Pt 8): 1676–1695.
13.
PfefferbaumAMathalonDHSullivanEV, et al. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol1994; 51(9): 874–887.
14.
BermelRABakshiR. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol2006; 5(2): 158–170.
15.
De StefanoNGiorgioABattagliniM, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology2010; 74(23): 1868–1876.
16.
RoosendaalSDBendfeldtKVrenkenH, et al. Grey matter volume in a large cohort of MS patients: Relation to MRI parameters and disability. Mult Scler2011; 17(9): 1098–1106.
17.
ArnoldDLRiessGTMatthewsPM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol1994; 36(1): 76–82.
18.
BergerTStüveO. Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis. Neurology2019; 92(10): 451–452.
19.
KuhleJBarroCDisantoG, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler2016; 22(12): 1550–1559.
20.
DisantoGBarroCBenkertP, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2017; 81(6): 857–870.
21.
KuhleJNourbakhshBGrantD, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology2017; 88(9): 826–831.
22.
NovakovaLZetterbergHSundstromP, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology2017; 89(22): 2230–2237.
23.
LucchinettiCBruckWParisiJ, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol2000; 47(6): 707–717.
24.
van NieropGPvan LuijnMMMichelsSS, et al. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol2017; 134(3): 383–401.
25.
Machado-SantosJSajiETroscherAR, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain2018; 141(7): 2066–2082.
26.
BarnettMHPrineasJW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol2004; 55(4): 458–468.
27.
HussainRZHayardenyLCravensPC, et al. Immune surveillance of the central nervous system in multiple sclerosis—Relevance for therapy and experimental models. J Neuroimmunol2014; 276(1–2): 9–17.
28.
PohlDRostasyKJacobiC, et al. Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol2010; 257(2): 212–216.
29.
BanwellBKruppLKennedyJ, et al. Clinical features and viral serologies in children with multiple sclerosis: A multinational observational study. Lancet Neurol2007; 6(9): 773–781.
30.
LunemannJDHuppkePRobertsS, et al. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology2008; 71(13): 1033–1035.
31.
CepokSZhouDSrivastavaR, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest2005; 115(5): 1352–1360.
32.
LunemannJDEdwardsNMuraroPA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain2006; 129(Pt 6): 1493–1506.
RiversTMSpruntDHBerryGP. Observations on attempts to produce acute disseminated encephalomyelitis. J Exp Med1933; 58(1): 39–53.
35.
PatersonPY. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med1960; 111: 119–136.
36.
Ben NunAWekerleHCohenIR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol1981; 11(3): 195–199.
37.
LevyHAssafYFrenkelD. Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol2010; 226(1): 148–158.
38.
SpathSKomuczkiJHermannM, et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. Immunity2017; 46(2): 245–260.
39.
MartinRJaraquemadaDFlerlageM, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol1990; 145(2): 540–548.
40.
OtaKMatsuiMMilfordEL, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature1990; 346(6280): 183–187.
41.
PetteMFujitaKWilkinsonD, et al. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA1990; 87(20): 7968–7972.
42.
GettingsEJHackettCTScottTF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler2015; 21(5): 670.
43.
GerdesLAHeldKBeltranE, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol2016; 80(2): 294–300.
44.
CaoYNylanderARamananS, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology2016; 86(16): 1553–1556.
45.
OkudaDTMowryEMBeheshtianA, et al. Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome. Neurology2009; 72(9): 800–805.
46.
SteinmanL. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry. Proc Natl Acad Sci USA1996; 93(6): 2253–2256.
47.
SchlagerCKornerHKruegerM, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature2016; 530(7590): 349–353.
48.
KrishnamoorthyGSaxenaAMarsLT, et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med2009; 15(6): 626–632.
49.
DenicAJohnsonAJBieberAJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology2011; 18(1): 21–29.
50.
TsunodaIFujinamiRS. Inside-Out versus Outside-In models for virus induced demyelination: Axonal damage triggering demyelination. Springer Semin Immunopathol2002; 24(2): 105–125.
51.
LocatelliGWortgeSBuchT, et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci2012; 15(4): 543–550.
52.
TrakaMArasiKAvilaRL, et al. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain2010; 133(10): 3017–3029.
53.
TrakaMPodojilJRMcCarthyDP, et al. Oligodendrocyte death results in immune-mediated CNS demyelination. Nat Neurosci2016; 19(1): 65–74.
54.
PerronHGenyCLaurentA, et al. Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol1989; 140(6): 551–561.
55.
PerronHLalandeBGratacapB, et al. Isolation of retrovirus from patients with multiple sclerosis. Lancet1991; 337(8745): 862–863.
56.
HancksDCKazazianHHJr.Roles for retrotransposon insertions in human disease. Mob DNA2016; 7: 9.
57.
MedinaJPerronH. DNA sequences from mobile genetic elements, a hidden half of the human genome. Med Sci2017; 33(2): 151–158.
58.
KuryPNathACreangeA, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med2018; 24(4): 379–394.
59.
BelshawRPereiraVKatzourakisA, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci USA2004; 101(14): 4894–4899.
60.
FeschotteCGilbertC. Endogenous viruses: Insights into viral evolution and impact on host biology. Nat Rev Genet2012; 13(4): 283–296.
61.
SerraCMameliGArruG, et al. In vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis. J Neurovirol2003; 9(6): 637–643.
62.
UleriEMeiAMameliG, et al. HIV Tat acts on endogenous retroviruses of the W family and this occurs via Toll-like receptor 4: Inference for neuroAIDS. AIDS2014; 28(18): 2659–2670.
63.
RuprechtKObojesKWengelV, et al. Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: Implications for multiple sclerosis. J Neurovirol2006; 12(1): 65–71.
64.
BrudekTLuhdorfPChristensenT, et al. Activation of endogenous retrovirus reverse transcriptase in multiple sclerosis patient lymphocytes by inactivated HSV-1, HHV-6 and VZV. J Neuroimmunol2007; 187(1–2): 147–155.
65.
BergalloMGallianoIMontanariP, et al. CMV induces HERV-K and HERV-W expression in kidney transplant recipients. J Clin Virol2015; 68: 28–31.
66.
MorandiETanasescuRTarlintonRE, et al. The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS ONE2017; 12(2): e0172415.
67.
RollandAJouvin-MarcheEViretC, et al. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol2006; 176(12): 7636–7644.
68.
SaresellaMRollandAMarventanoI, et al. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult Scler2009; 15(4): 443–447.
69.
PerronHDougier-ReynaudHLLomparskiC, et al. Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS ONE2013; 8(12): e80128.
70.
PerronHJouvin-MarcheEMichelM, et al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology2001; 287(2): 321–332.
71.
KremerDSchichelTForsterM, et al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol2013; 74(5): 721–732.
72.
LeypoldtFTitulaerMJAguilarE, et al. Herpes simplex virus–1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report. Neurology2013; 81(18): 1637–1639.
73.
ArmangueTMorisGCantarin-ExtremeraV, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology2015; 85(20): 1736–1743.
ShiraniAOkudaDTStüveO. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics2016; 13(1): 58–69.
76.
SormaniMPArnoldDLDe StefanoN. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol2014; 75(1): 43–49.
77.
International Multiple Sclerosis Genetics Consortium. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet2013; 92(6): 854–865.
78.
HainesJLTer-MinassianMBazykA, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group. Nat Genet1996; 13(4): 469–471.
79.
SawcerSJonesHBFeakesR, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet1996; 13(4): 464–468.
80.
RajTKuchrooMReplogleJM, et al. Common risk alleles for inflammatory diseases are targets of recent positive selection. Am J Hum Genet2013; 92(4): 517–529.
